10-Q: MIRA Pharmaceuticals Reports Third Quarter 2024 Financial Results, Advances MIRA-55 Development

MIRA Pharmaceuticals reported a net loss of $5.45 million for the nine months ended September 30, 2024, while advancing the development of its lead drug candidate, MIRA-55.

Summary

• MIRA Pharmaceuticals, a pre-clinical-stage pharmaceutical company, reported its financial results for the third quarter of 2024.
• The company is focused on developing two neuroscience programs, Ketamir-2 and MIRA-55, targeting neurological and neuropsychiatric disorders.
• For the nine months ended September 30, 2024, the company reported a net loss of $5.45 million, or $0.36 per share.
• Research and development expenses for the nine months totaled $2.4 million, primarily related to pre-clinical research projects.
• General and administrative expenses were $3.1 million for the same period, a decrease from $3.8 million in 2023 due to reduced stock-based compensation and IPO-related costs.
• The company's cash balance was $4.14 million as of September 30, 2024.
• MIRA has identified a novel and improved version of its molecule, MIRA-55, which is now the lead compound for its oral pharmaceutical marijuana drug candidate.
• The company has filed a provisional patent for MIRA-55, which encompasses all pre-clinical studies.
• MIRA expects to fund operations through the fourth quarter of 2025 with current cash on hand and potential stock issuances.
• The company has an active ATM offering agreement to sell up to $75 million of common stock.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in identifying and advancing MIRA-55, the financial results are weak, with significant losses and concerns about the company's ability to continue as a going concern. The need for additional funding and the ineffectiveness of disclosure controls are also negative factors.

Positives

• The company has identified an improved molecule, MIRA-55, which is now the lead drug candidate.
• MIRA has filed a provisional patent for MIRA-55, securing intellectual property rights.
• General and administrative expenses have decreased compared to the previous year.
• The company has an active ATM offering agreement to raise additional capital.
• The DEA has concluded that neither Ketamir-2 nor MIRA-55 would be considered controlled substances.

Negatives

• The company reported a net loss of $5.45 million for the nine months ended September 30, 2024.
• The company has used approximately $3.8 million of cash in operations during the nine months ended September 30, 2024.
• The company does not have sufficient cash to support operations for at least the next 12 months.
• The company has a history of substantial losses.
• The company's disclosure controls and procedures were not effective as of June 30, 2024.

Risks

• The company's ability to fund ongoing operations and future clinical trials is dependent on obtaining significant additional external funding.
• The company has a history of substantial losses and expects to continue to generate losses in the foreseeable future.
• The company's disclosure controls and procedures were not effective as of June 30, 2024.
• The company relies on third parties for pre-clinical trials, which could lead to delays.
• Geopolitical events and global economic conditions may impact third-party suppliers and manufacturers.

Future Outlook

The company expects to fund operations through the fourth quarter of 2025 with current cash on hand and potential stock issuances under its shelf registration statement. The company expects to continue to generate losses in the foreseeable future.

Management Comments

• Management believes that MIRA-55 is an improvement over MIRA1a in that it displays enhanced potency and potential for efficacy.
• Management is in the process of implementing plans to remediate the ineffectiveness of its disclosure controls and procedures through enhancements to its internal control environment.

Industry Context

MIRA Pharmaceuticals operates in the competitive pharmaceutical industry, focusing on developing novel treatments for neurological and neuropsychiatric disorders. The company's focus on oral formulations and non-controlled substances aligns with a trend towards patient-friendly and accessible treatments. The development of MIRA-55, a novel oral pharmaceutical marijuana, positions the company in a growing market for cannabinoid-based therapies.

Comparison to Industry Standards

• MIRA Pharmaceuticals is a pre-clinical stage company, so direct comparisons to revenue-generating pharmaceutical companies are not applicable.
• The company's R&D spending of $2.4 million for the nine months ended September 30, 2024, is typical for a company at this stage of development.
• The net loss of $5.45 million is also typical for a pre-clinical stage company that is investing heavily in research and development.
• The company's cash balance of $4.14 million is relatively low, highlighting the need for additional funding.
• Compared to other biotech companies, MIRA's reliance on external funding is a common theme, as is the need to manage cash burn while advancing drug candidates.
• Companies like Zynerba Pharmaceuticals and Corbus Pharmaceuticals are also developing cannabinoid-based therapies, but they are at a more advanced stage of clinical development.

Related Party Transactions

• The company received payment from a related party in the amount of $0.03 million for costs of shared management resources.
• The company incurred $0.04 million in costs related to shared management resources.
• The company had a loan agreement with MIRALOGX, LLC, a related party, for up to $3.0 million, but no funds were borrowed as of September 30, 2024.
• The company had a loan agreement with Bay Shore Trust, a related party, which was repaid in 2023.
• The company settled a claim submitted by certain shareholders under Section 16 of the Securities Exchange Act involving the company that claimed illegal profits were earned on stock transactions involving insiders of the company, resulting in a disgorgement of $148,703 by Bay Shore Trust.

Stakeholder Impact

• Shareholders face the risk of further dilution due to the company's need for additional funding.
• Employees may be impacted by the company's financial challenges and potential restructuring.
• Customers and suppliers are not directly impacted at this pre-clinical stage, but their future relationships will depend on the company's ability to secure funding and advance its drug candidates.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company will continue to advance the development of MIRA-55 as its lead compound.
• The company will continue to seek additional funding through its ATM offering and other potential sources.
• The company will work to remediate the ineffectiveness of its disclosure controls and procedures.
• The company will continue pre-clinical research projects for both MIRA-55 and Ketamir-2.

Key Dates

Keywords

MIRA Pharmaceuticals, MIRA-55, Ketamir-2, pharmaceutical, pre-clinical, neuropathic pain, depression, neuropsychiatric disorders, ATM offering, clinical trials